Sweden
· Delayed Price · Currency is SEK · Price in DKKCurasight Company Description
Curasight A/S, a biotech company, develops treatment of cancer.
The company exploits a novel Positron Emissions Tomography (PET) imaging platform that targets the urokinase-type plasminogen activator receptor (uPAR).
It develops uTRACE for enhanced evaluation of cancer disease across several cancer types has been confirmed in multiple phase II clinical trials; and uTREAT, a uPAR targeted radionuclide therapy is using uTRACE together with radiation therapy to irradiate cancer with limited irradiation of healthy tissue.
The company focuses on generating data with uTRACE and uTREAT in cancers, including prostate cancer, glioblastoma (brain cancer), neuroendocrine tumors, head and neck cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer.
Curasight A/S was incorporated in 2013 and is based in Copenhagen, Denmark.
| Country | Denmark |
| Founded | 2013 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 4 |
| CEO | Ulrich Krasilnikoff |
Contact Details
Address: Ole MaalOees Vej 3 Copenhagen, 2200 Denmark | |
| Phone | 45 22 83 01 60 |
| Website | curasight.com |
Stock Details
| Ticker Symbol | CURAS |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Ulrich Krasilnikoff | Chief Executive Officer |
| Ulrich Krasilnikoff | Chief Financial Officer |
| Hanne Jensen | Chief Operating Officer |